Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Definitive chemoradiation with cisplatin + irinotecan versus carboplatin + paclitaxel in esophageal cancer
IRCT2014110219783N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- May 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in esophageal cancer and esophagogastric junction cancer comparing Cisplatin + irinotecan chemoradiation with Carboplatin + paclitaxel chemoradiation (2 arms). Started May 2016; status: completed.
02
Drugs
cisplatinirinotecancarboplatinpaclitaxel
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on IRCT2014110219783N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2014110219783N1.